The Science

What is NAD+?

NAD+ aids other enzymes to function correctly which then helps multiple processes in our bodies ranging from brain cell growth to repairing DNA to assisting mitochondria to generate energy from food. Essentially, NAD+ plays a critical role in maintaining cellular and metabolic functions, which translates to better health and longevity of our cells, organs, and bodies as a whole.

Finding ways to boost your NAD levels has become the key to a longer life.

What happens to NAD+ levels as we age?

As we age, our natural levels of NAD+ decline, and it is believed that this is the reason for many age-related diseases.

The other problem with NAD+ is that it is too large a molecule to cross the cell membrane barrier.

Studies have shown that supplementing with NMN, or nicotinamide mononucleotide, can raise your NAD+ levels.

NAD+ is essential for our cells to function. It transports energy & power mitochondria.

It is essential to maintain optimum cellular NAD+ to ensure we age healthy.

Human clinical trials have demonstrated the benefits of supplementing with NMN.

Safety & Efficacy

STUDY 1

Physical Performance

STUDY 2

Insulin Sensitivity

STUDY 3

Cardiovascular Health

STUDY 4

DNA Repair

STUDY 5

STUDY # 1

CLINICAL RESEARCH FINDINGS

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

CONCLUSIONS

  • Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to placebo group.
  • Blood NAD concentrations were highest in the groups taking 600 mg and 900 mg NMN. No safety issues, based on monitoring adverse events were found. NMN supplementation was well tolerated.
  • Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 with longest walking distances measured in the 600 mg and 900 mg groups.
  • NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily. Clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake.

ABSTRACT

A clinical trial of 80 healthy middle-aged adults given oral doses of NMN at 300 mg, 600 mg, or 900 mg over 60 days to evaluate blood NAD concentration with dose dependent regimens.

DATE: Feb 2023

STUDY # 2

CLINICAL RESEARCH FINDINGS

Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.

CONCLUSIONS

  • NMN administration safely increased circulating NAD levels in the test subjects.
  • Significant reduction seen in total LDL and non-HDL cholesterol, body weight and diastolic blood pressure.
  • These data provide the rationale for larger trials to further assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.

ABSTRACT

A clinical trial of 30 overweight or obese adults > 45 years given oral doses of NMN at 1000 mg or a placebo daily for 28 days to evaluate body weight, liver, muscle, intra-abdominal at, insulin sensitivity, blood pressure, lipids, physical performance, and muscle bioenergetics.

DATE: July 2023

STUDY # 3

CLINICAL RESEARCH FINDINGS

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

CONCLUSIONS

  • Insulin stimulated glucose disposal increased after NMN supplementation compared to the placebo group.
  • NMN supplementation up-regulated the expression of platelet-derived growth factor receptor β and other genes related to muscle re-modeling.
  • These results demonstrate that NMN increases muscle insulin sensitivity, insulin signalling, and re-modeling in women with prediabetes who are overweight or obese.

ABSTRACT

A 10 week clinical trial of postmenopausal women with prediabetes who were overweight or obese given oral doses of NMN at 250 mg or a placebo daily to evaluate the effect of NMN supplementation on metabolic function.

DATE: June 2021

STUDY # 4

CLINICAL RESEARCH FINDINGS

Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.

CONCLUSIONS

  • Oxygen uptake (VO2) and Ventilatory threshold (VT) increased to a greater degree in the group supplementing NMN at 600 mg/day and 1200 mg/day.
  • NMN increases the aerobic capacity of humans during exercise training, and the improvement is likely the result of enhanced O2 utilization of the skeletal muscle which appears to be one of the most sensitive tissues to NMN in humans.

ABSTRACT

A 6 week clinical trial of 48 young and middle-aged recreationally trained runners aged 27-50 years were given oral doses of either a placebo, NMN at 300 mg, 600 mg, or 1200mg daily to evaluate the effect of NMN supplementation on aerobic capacity of runners.

DATE: July 2021

STUDY # 5

CLINICAL RESEARCH FINDINGS

The Impacts of Short-Term NMN Supplementation on Serum Metabolism, Fecal Microbiota, and Telomere Length in Pre-Aging Phase.

CONCLUSIONS

  • The telomere length (TL) of clinical subjects was observed to have increased significantly after 30 days of NMN supplementation.
  • Telomere length has been documented as an important feature of aging and observed to shorten over time. The documented increase in TL from NMN supplementation suggests the potential of NMN use at a pre-aging phase to retard the proceeding of aging.

ABSTRACT

A 90 day clinical trial of 8 healthy men aged 45-60 years (pre-aging phase) given NMN at 300mg/day dosage to evaluate the supplementary effect on the telomere length of the peripheral blood mononuclear cell (PBMC).

DATE: November 2021